Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Anti-TF mAb immobilized on CM5 Chip can bind Human Tissue Factor, Fc Tag (Cat. No. TF3-H5253) with an affinity constant of 2.38 nM as determined in SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Tisotumab vedotin | TF-011-MMAE | Approved | Genmab A/S | HuMax-TF, TIVDAK | United States | Uterine Cervical Neoplasms | Seagen Inc | 2021-09-20 | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| hI-con1 | ICON-1; hI-con1 | Yale University | Details | ||
| Recombinant NAPc2 | AB-201 | Phase 3 Clinical | Dendreon Uk Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| MRG004A | MRG004A | Phase 2 Clinical | Shanghai Miracogen Inc | Solid tumours | Details |
| XB-002 | ICON-2; XB-002 | Phase 1 Clinical | Iconic Therapeutics Inc | Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Urogenital Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
